
==== Front
Target Oncol
Target Oncol
Targeted Oncology
1776-2596
1776-260X
Springer International Publishing Cham

38954182
1078
10.1007/s11523-024-01078-5
Review Article
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents
Somaiah Neeta 1
Paudyal Bishnuhari 2
Winkler Robert E. 2
Van Tine Brian A. 3
Hirbe Angela C. hirbea@wustl.edu

4
1 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 Chair of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
2 grid.518922.5 0000 0004 8359 5248 Ascentage Pharma Group Inc., Rockville, MD USA
3 grid.516080.a 0000 0004 0373 6443 Medicine and of Pediatrics, Developmental Therapeutics (Phase 1) Program, Sarcoma Program, Washington University School of Medicine, Barnes and Jewish Hospital, Siteman Cancer Center, St. Louis, MO USA
4 grid.516080.a 0000 0004 0373 6443 Medicine and Pediatrics, Adult Neurofibromatosis Clinical Program, Division of Oncology, Sarcoma Section, Couch Building, Room 3304, Washington University School of Medicine, Barnes Jewish Hospital, Siteman Cancer Center, 660 S. Euclid Avenue, Campus, Box 8076, St. Louis, MO 63110-1010 USA
2 7 2024
2 7 2024
2024
19 5 665678
30 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Background

Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs.

Objective

The chief aim of this review is to consider the epidemiology, histology, anatomic distribution, pathologic signaling pathways, diagnosis, and management of MPNST, with a focus on potential targeted therapies. A subordinate objective was to establish benchmarks for the antitumor activity of such treatments.

Results

MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. Spindle-cell sarcomas of neural-crest origin, MPNSTs are frequently situated in the extremities and pelvis/trunk, often at the confluence of large nerve roots and bundles. Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. A combination of magnetic resonance imaging (MRI) and positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) enables comprehensive assessment of both morphology and metabolism, while MRI- and ultrasound-guided core needle biopsy can confirm histopathology. Although surgery with wide excisional margins is now the chief curative approach to localized disease, MPNST-specific survival has not improved in decades. For advanced and metastatic MPNST, radiation and chemotherapy (chiefly with anthracyclines plus ifosfamide) have somewhat promising but still largely uncertain treatment roles, chiefly in local control, downstaging, and palliation. No single druggable target has emerged, no objective responses have been observed with a number of targeted therapies (cumulative disease control rate in our review = 22.9–34.8%), and combinatorial approaches directed toward multiple signal transduction mechanisms are hallmarks of ongoing clinical trials.

Conclusions

Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

http://dx.doi.org/10.13039/100019621 Ascentage Pharma issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcKey Points

Malignant peripheral nerve sheath tumors are rare, aggressive cancers that tend to recur and metastasize, and have an extremely poor prognosis.	
Although surgery is potentially curative in localized disease, and despite major advances in unravelling the molecular biology, there is no standard of targeted medical therapy.	

Introduction

Malignant peripheral nerve sheath tumors (MPNSTs) are a rare group of aggressive cancers with a poor prognosis because of their high potential for local recurrence and metastasis. For localized disease, surgical resection with or without radiation is the only potentially curative option. Postsurgically, the 5-year median overall survival (OS) rate ranges from 30 to 60% [1]. Patients with metastatic disease have a poor OS [2]. Disease-specific survival (DSS) has not improved appreciably in recent decades. MPNST constitutes the main cause of morbidity and mortality in patients with the inherited condition of neurofibromatosis type-1 (NF1) [3].

MPNSTs often exhibit extensive nerve involvement and infiltration of surrounding structures, which can render them inoperable. The median OS and progression-free survival (PFS) in patients with unresectable MPNST are less than 5 and 2 months, respectively, in trials of investigational agents [4]. The generally poor outcomes for patients with MPNST after surgery, radiation therapy, and/or chemotherapy underscore an unmet medical need for novel disease-specific therapies.

Epidemiology

Accounting for approximately 2–10% of the 13,590 soft-tissue sarcomas (STS) diagnosed annually in the USA, MPNST is considered the sixth most common type of STS, which in turn comprises < 1% of all malignancies [5–7]. About 40–50% of cases occur in association with NF1 (von Recklinghausen’s disease), while 40–47% are sporadic [8]. A history of radiation exposure is present in approximately 10–13% of MPNST cases, with a typical latency period exceeding 16 (range 4–41 [9]) years [8, 10, 11].

In patients with NF1, about 95% have small, benign dermal neurofibromas, and 30% or more develop larger plexiform neurofibromas [12]. NF1-associated plexiform neurofibromas have an approximately 10% risk of malignant transformation [9], with a higher overall risk in more centrally located neoplasms of the torso and proximal limbs as well as large nerve trunks [13].

Sporadic MPNSTs are typically diagnosed in patients ages 30–50 (mean 41 [5]) years [13], while NF1-associated MPNST is more likely to occur in younger patients, typically between 20 and 40 years old [13]. However, MPNST can have a pediatric onset. One study following 52 NF1 patients with MPNST for 20 years included 8 patients ages 1–17 years (mean 12 years) [14], and one case report described MPNST in a 20-month-old toddler [15]. It is not clear if one sex is affected more than the other [7]. Patients with NF1 have a lifetime risk of 8–13% of developing MPNST (versus 0.001% in the general population) [16].

A cohort study found that, of 666 (1607 total) patients with NF1 who developed additional neoplasms (other than neurofibromas), 295 (18.4% of the total) had gliomas and 243 (15.1%), MPNSTs [17]. Compared with the general population, patients with NF1 tended to develop a range of tumors, including MPNSTs, at a younger age (mean 33.88 versus 47.06 years; p < 0.0001). Compared with patients with NF1 who developed other neoplasms, those with MPNSTs had a significantly lower 5-year DSS (31.6 versus 92.4%; p < 0.001).

A large tumor registry at The University of Texas MD Anderson Cancer Center [8] documented respective 5-year DSS, local recurrence-free survival (LRFS), and distant recurrence-free survival (DRFS) rates of 53.6, 56.6, and 49.6%, respectively, in patients with high-grade MPNST, including a lower 5-year DSS in NF1- (52%) and radiation- (47%) associated MPNST compared with sporadic cases (67%).

A study of 95 Korean patients diagnosed with MPNST and treated over a 27-year interval further documented differences between NF1-associated and sporadic varieties [18]. Compared with their counterparts with sporadic MPNST, patients with a history of NF1 had a significantly greater tumor size (median 8.2 versus 5.0 cm; p < 0.001), lower median age at diagnosis (32 versus 45 years; p = 0.012), and a greater number of imaging studies and surgical procedures (each p ≤ 0.004). The 10-year OS rate for localized MPNST was also significantly reduced in those with NF1-associated tumors (45% ± 11% versus 60% ± 8%; p = 0.046). A European survival meta-analysis involving more than 1800 patients found that, although the odds ratios for OS and DSS were significantly higher in patients without (versus with) NF1, this gap in survival has been narrowing in recent years [19].

A retrospective review of 175 patients diagnosed with MPNST at the Mayo Clinic from 1985 to 2010 revealed 5- and 10-year DSS rates of 60 and 45%, respectively, as well as a local recurrence rate of 22% [22]. Significant adverse prognostic factors on multivariate analysis included tumor size ≥ 5 cm, location in the trunk, local recurrence, and high tumor grade [20]. Finally, a meta-analysis involving 28 studies from 1966 through 2020 found that the pooled 5-year OS rate was 49%, local recurrence rate 38%, and event-free survival rate 37% [21].

Histopathology, Anatomic Distribution, and Presentation

Previously termed “malignant Schwannoma,” MPNST is considered a spindle-cell sarcoma arising in cells of neural-crest origin in which fibroblasts are frequently present. A “herringbone” or “marbled” fascicular spindle-cell growth or a branching pattern of hemangiopericytoma-like vasculature may be observed, with light hypocellular areas alternating with dark hypercellular regions [22]. MPNSTs tend to be very cellular lesions, with pleomorphism, nuclear hyperchromasia, and coagulative necrosis and high mitotic activity [9, 22]. (A small proportion of MPNSTs have a solely epithelioid morphology [9].) Up to 15% of MPNSTs include heterologous elements, including glands with a benign appearance, angiosarcomatous foci, and bony or cartilaginous islands [23].

MPNSTs are frequently situated in the proximal lower and upper extremities and the pelvis, often at the confluence of large nerve roots and bundles. These include peripheral nerves, sciatic nerves, as well as the brachial and sacral plexi and spinal nerve roots. Other sites include the head and neck (including the brain), trunk/core/retroperitoneum, and, less frequently, skin, gastrointestinal tract (mesentery, bile duct, colon, and rectum), endocrine glands (thyroid), and prostate and breast [9]. Gross pathology may include fusiform nerve enlargement [9].

A Surveillance, Epidemiology, and End Results (SEER) program database analysis involving 3267 patients with MPNST from 1973 to 2013 [24] showed the following anatomic distribution: core, n = 1307 (40.0%); limb, n = 1022 (31.3%); head and neck, n = 449 (13.7%); cranium, n = 167 (5.1%); and spine, n = 119 (3.6%). Independent factors associated with decreased survival in some series [25] include tumor size, stage, older age, and partial resection/positive margins.

MPNST typically presents as a soft-tissue mass or swelling, often enlarging over a period of several months, with potential local/radicular pain, paresthesia, or paraparesis (on disease progression). Mixed sensory and motor symptoms are suggestive findings because neurologic deficits are infrequent in patients with benign masses. Incident pain in a patient with NF1 should trigger assessment for MPNST [23].

As mentioned, the prognosis is poor, with typically rapid growth and metastasis (mainly to the lungs more often than the bone or liver). In addition to frequent metastasis and disease recurrence, patients with MPNST are also approximately 30 times more likely than the general population to develop secondary malignancies, particularly in the breast, skin, lung, and soft tissues in females as well as skin and myeloid tissues in males [26].

Genetics and Pathogenesis: Potential Cellular and Molecular Signaling Pathways

A complex network of signaling pathways underlies the oncogenesis and progression of MPNST. These diverse pathways may open avenues for the development of targeted pharmacotherapies.

Genomic Alterations

Copy Number Alterations

MPNSTs are highly copy number aberrant and enriched in chromosome 8 [27]. Chromosome 8 gain, as well as aberrations in chromosomes 1, 12, 22, and 17 (on which the NF1 gene is located: 17q11.2), have been observed [11]. Regions with potentially relevant proto-oncogenes include chromosome bands 5p15, 7p11-p13, 8q22-q24, 12q21-q24, and 17q24-25 [28].

Mutations and Downstream Pathway Alterations

Inactivating mutations in the NF1 gene may contribute to MPNST oncogenesis through loss of the Ras-inhibiting enzyme neurofibromin. Attendant activation of Ras and its downstream pathways culminates in upregulation of phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)/mitogen-activated protein kinase (MAPK) signal transduction mechanisms, which in turn regulate tumor cell proliferation, survival, angiogenesis, and metastasis. In this context, a preclinical study demonstrated synergistic effects of everolimus and an inhibitor of the MEK component of the MAPK pathway (PD-901) in increasing lifespan and decreasing tumor burden, but this has yet to translate into a clinical trial [29]. The SARC031 trial (NCT03433183) involving MEK inhibitor selumetinib combined with mTOR inhibitor sirolimus in patients with unresectable or metastatic MPNST demonstrated that partial metabolic responses (by PET PERCIST) did not translate into enhanced treatment outcomes [30].

Loss of NF1 gene expression is considered a necessary but not sufficient condition for MPNST development [31]; other cooperating genetic (and epigenetic) events are required. These may include inactivating mutations of the TP53 tumor suppressor gene, loss of tumor suppressor phosphatase and tension homolog (PTEN), amplification of epidermal growth factor receptor (EGFR), Trp53 loss, and Ink4a deletion or inactivation [32–37]. According to one research team, the finding that “many [human] MPNST are Ink4/Arf deficient but p53 competent provides a unique window of therapeutic opportunity for drugs such as MDM2 and/or CDK4/6 inhibitors as potential avenues of treatment.” [38] Genetic alterations that are prominent in MPNST include EGFR overexpression, TP53 alteration, and loss of PTEN and cyclin-dependent kinase inhibitor 2A (CDKN2A) [39–43].

The polycomb repressive complex 2 (PRC2) and its components/subunits are salient epigenetic regulators with potential molecular pathological roles in MPNST. These include enhancer of zeste homolog 2 (EZH2), embryonic ectoderm development (EED), and SUZ12. EED and SUZ12 genetic aberrations are considered to be among the most common somatic mutations in patients with MPNST. Loss-of-function somatic mutations in EED and/or SUZ12 are observed in 90% of radiation-associated, and 70% of NF1-associated, MPNSTs [44]. Preclinical research has demonstrated that EED or SUZ12 loss results in PRC2 inactivation, which in turn drives MPNST cell growth and metastasis (including upregulation of matrix-remodeling enzyme and collagen-dependent invasiveness), with amplification of Ras-driven transcription. In clinical samples, PRC2 loss correlated with elevated fibrosis, metastasis, and reduced patient survival [45].

SUZ12 mutation may be part of a “three-hit” sequence that converts neurofibromas to MPNSTs, with the earlier hits including germline NF1 mutation (first hit) and somatic (NF1 allele) inactivation from the nonaffected parent (second hit) [46]. Finally, preclinical research suggests that inhibition of the EZH2–miR-30d–KPNBI signaling pathway may be a viable targeted treatment strategy to inhibit MPNST cell growth and survival [47, 48].

Ras-driven transcriptome analysis of 2000 candidate genes (of which 339 showed significantly differential expression in human and murine NF1-associated tumors) demonstrated that the Aurora kinase A (AURKA) gene was amplified and overexpressed in MPNSTs (but not neurofibromas). An AURKA inhibitor and short-hairpin RNAs attenuated MPNST cell growth, while AURKA-selective inhibitor MLN8237 significantly augmented survival and stabilized tumor volume in murine MPNST xenograft models [49].

Activating mutations in TYK2 have also been identified in a subgroup of NF1-associated MPNST tumors [50]. TYK2 encodes a JAK-family protein that mediates cytokine signaling via the STAT pathway and hence may affect transcription of genes regulating cancer cell apoptosis, survival, proliferation, and invasiveness. The combination of TYK2 and MEK inhibition has also shown promising in vivo effects in a preclinical model. When combined, TYK2 inhibitors (e.g., deucravacitinib [BMS-986165]) and a MEK inhibitor (mirdametinib) exerted synergistic antiproliferative and apoptogenic effects in MPNST cell lines. Clinical trials may be warranted to determine the utility of combining TYK2 and MEK inhibitors to treat MPNST.

AXL is a receptor tyrosine kinase associated with the survival, growth, and metastasis of MPNST cells. Expressed in more than 90% of MPNSTs and neurofibromas, AXL may be activated and abnormally expressed as an early event in MPNST development, conferring a tumor cell survival advantage by stimulating the PI3K/mTOR/MAPK prosurvival pathways as well as other signal transduction mechanisms related to cellular migration, growth, and invasiveness. A preclinical study demonstrated that pharmacologic inhibition of AXL and MEK1/2 decreased MPNST tumor volumes [51].

Another multifunctional tyrosine kinase receptor involved in tumor cell survival, proliferation, DNA repair, and differentiation is insulin-like growth factor-1 receptor (IGF1R). MPNST tissue samples show enrichment of IGF1R pathway copy number-altering events, including IGF1R gene amplification. A preclinical study showed that high IGF1R protein expression was related to inferior tumor-free survival and that pharmacologic inhibition of IGF1R resulted in reduced cellular invasiveness, proliferation, and migration, with decreased PI3K/AKT/MAPK signaling [52].

A further potential druggable cell membrane target is platelet-derived growth factor receptor A (PDGFRA). In an animal model, overexpression of wild-type PDGFRA (expressed by about 78% of human MPNSTs) in cells of neural-crest origin was associated with loss of NF1 and resulted in abnormal downstream Ras signaling and stimulated MPNST oncogenesis (tumorigenicity) [53].

Tumor Microenvironment (TME)

Cells and factors in the TME likely provide additional growth factors or chemokines (e.g., CXCL12) that accelerate the growth and progression of MPNSTs [54]. A receptor for the cytokine interleukin-13 [IL-13-receptor alpha 2 (IL-13Rα2)] is also overexpressed by MPNSTs. This receptor enables cancer cells to avoid death by binding to IL-13 without α1 receptor activation, and decreased α1 activation in turn augments tumor cell survival and metastasis; IL-13Rα2 also potentiates cancer metastasis and invasiveness by activating STAT3, PI3K, ERK, and AKT [55].

Expression of the hypoxia-inducible factor (HIF-1α) has been reported in approximately 75% of MPNST cases and is a poor prognostic factor [56]. Of potential interest, a preclinical study demonstrated the inter-relatedness of transcriptional factor STAT3 and HIF. STAT3 knockdown blocked HIF1α, HIF2α, and VEGF expression in four MPNST cell lines. Not only did targeted inhibition of STAT3 suppress tumorigenesis, cellular migration, and invasiveness, but these processes were dependent on HIF signaling, and HIF1α knockdown abolished these

STAT3-driven effects [57].

In addition, MPNSTs typically exhibit low or absent expression of PD-L1 and lack of PD-1 expression, with significant infiltration of CD8+ tumor-infiltrating lymphocytes and M2 macrophages [58, 59]. A large analysis of tumor-associated biomarkers in different forms of sarcoma found that macrophages comprised more than half of the total tumor immune infiltrates and that the M2:(M0 + M1) ratio in MPNST was 2.1:1 [59]. No signal for treatment has been seen for MPNSTs in immunotherapy-based clinical trials to date.

An immunohistochemical analysis found a significant increase in vascular density in MPNSTs compared with benign neoplasms. Although VEGF expression was significantly increased in MPNST compared with benign neoplasms (and basic fibroblast growth factor expression increased in neurofibromas versus normal Schwann cells), malignant transformation may require coordinated rises in VEGF receptors, EGFR expression, and TME mast cells, which can transmit inflammatory signals and stimulate angiogenesis in different kinds of tumors [60].

An extracellular matrix protein with properties of cytokines, osteopontin (OPN) was initially identified in osteosarcoma cells and mediates a range of potential cellular functions, including communication, immune-cell activation and migration, and adhesion. An analysis of copy number and gene expression in MPNSTs found an 85-fold increased expression in the secreted phosphoprotein 1 (SPP1) gene as compared with plexiform neurofibromas. Short-hairpin RNA knockdown of SPP1 in NF1-associated MPNST cells was associated with decreased tumor size and invasiveness across four MPNST cell lines [61].

Finally, recent preclinical work has identified a previously unrecognized mesenchymal stem-like subpopulation (nestin+ cells) underlying malignant transformation, with regulation by potentially druggable targets governing epithelial-mesenchymal transition and “stemness,” such as ALDH1A1 and ZEB1 [62]. Other dysregulated cellular and molecular pathways in MPNST are shown in Table 1 [23].Table 1 Dysregulated molecular pathways in MPNST

Pathway	Normal role	Change in MPNST	
NF1	Tumor suppressor	Downregulated	
PTEN	Tumor suppressor

Negative regulator of PI3K/AKT/mTOR signaling cascade

	Downregulated	
PDGFRα	Angiogenesis, activator of cells of mesenchymal origin	Upregulated	
CDKN2A/p16	Tumor suppressor	Downregulated	
IGF1R	Positive regulator of PI3K/AKT/mTOR cascade	Upregulated	
EGFR	Positive regulator of PI3K/AKT/mTOR cascade	Upregulated	
MAPK	Phosphorylation of RAF/MEK/ERK cascade	Upregulated	
TYK2 [50, 96]	JAK protein receptor-associated kinase mediating cytokine signaling via phosphorylation of STAT proteins	Upregulated	
SHP2 [97, 98]	Encoded by PTPN11, facilitation by SHP2 of RAS-GEF-mediated RAS-GTP loading and RAS membrane recruitment required for RTK-mediated RAS/ERK activation	Upregulated	
Adapted from Grobmyer et al. [9], with permission from John Wiley and Sons, and James et al. [23], with permission from Elsevier

Diagnosis

In general, computed tomography (CT) and magnetic resonance imaging (MRI) help to establish tumor stage, size, and local invasiveness. MPNST is usually diagnosed as an enlarging soft-tissue mass infiltrating a peripheral nerve. Although one study showed that the mean tumor size of MPNSTs (7.4 ± 4.1 cm) was significantly greater than their benign counterparts (4.8 ± 2.7 cm; p = 0.008) [63], some degree of overlap in the sizes of these lesions may limit the clinical utility of using size as a discriminator. Similarly, frequent inhomogeneity of MPNSTs may challenge MRI to reliably discriminate between MPNSTs and benign lesions [23].

Diagnosis may be suspected before biopsy on the basis of symptoms, 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) uptake on positron emission tomography (PET; in patients with plexiform neurofibromas), or relationship to a prior neurofibroma or a peripheral nerve [23]. On MRI, apparent diffusion coefficient (ADC) based on diffusion-weighted imaging (DWI) may help to discriminate MPNSTs from plexiform neurofibromas and identify MPNST in patients with NF1 [64, 65]. Concomitant FDG-PET/MRI enables comprehensive evaluation of both morphology (MRI) and metabolic data (PET) to correlate metabolic activity with lesion growth [66].

One potential diagnostic challenge is overlapping signs and symptoms of MPNST and benign lesions (Table 2) [23]. CT, contrast-enhanced MRI, and ultrasonography are important modalities to distinguish them. Core needle biopsy guided by MRI or ultrasound is used to confirm histopathology, which, along with clinical assessment, is considered the criterion standard of MPNST diagnosis [23].Table 2 Diagnostic criteria for MPNST

Using MRI (MPNST versus benign PNST)	
	MPNST	Benign PNST	
Parameter	
Tumor size, mm	74–100	43–69	
Intratumoral lobulation, %	50–63	12–17	
Intratumoral heterogeneity, %	51–90	30–52	
Irregular or peripheral contrast enhancement, %	34–75	5–33	
Intratumoral cystic changes, %	21–39	10–17	
Peritumoral edema, %	29–66	0–23	
Histologic criteria (low-grade MPNST versus neurofibroma)	
	Low-grade MPNST	Neurofibromaa	
Characteristic	
Nuclear atypia	Generalized	Focal or diffuse	
Cellularity	Diffuse	Not diffuse	
Mitotic activity	Low levels	None	
aNeurofibromas with atypical features are characterized by nuclear atypia, cellularity, and/or mitotic activity that falls short of the criteria for low-grade MPNST. Reproduced from James et al. [23] with permission from Elsevier

Pathologic diagnostic challenges include discriminating: (1) high-grade MPNSTs from other high-grade tumors and (2) low-grade MPNSTs from neurofibromas and/or atypical neurofibromas (Table 2). On hematoxylin and eosin staining, a range of high-grade sarcomas and other tumors may have similar spindle-cell morphology to MPNST [23]. A potential future diagnostic aid is cell-free DNA ultra-low-pass whole-genome sequencing [67].

Proactive monitoring of patients with NF1 may assist in surveillance for malignant transformation to MPNST. For instance, the total volume and number of neurofibromas are significantly correlated with the risk of such transformation. Potentially prodromic manifestations in patients with NF1 include hardening of soft neurofibromas, sleep disturbances, prolonged pain, and new neurologic deficits (including loss of sphincter control) [13]. The following conditions may warrant particularly vigorous monitoring: early MPNST diagnosis, a history of radiation therapy, as well as plexiform neurofibromas situated in the abdominal and pelvic regions, lumbosacral and shoulder plexi, and spinal nerve roots [13].

Potential Treatments

Surgery

Radical surgical treatment with wide local excisional margins is the standard of care for localized high-grade MPNST and is positively associated with life expectancy [23, 68]. Referral to a specialized center, together with multidisciplinary care involving surgical oncology experts, clinical geneticists, specialized neuropathologists, and radiation therapists, is a hallmark of effective surgical care [68]. Using a wide approach to the lesion and taking care not to rupture the tumoral capsule, an incision is made over the tumor, oriented along the nerve’s anatomical track, with palpation of the tumor and/or ultrasonography to assist in localizing tumors that are not palpable. Thoracic and abdominal CT screening may play a role in identifying any secondary lesions [68]. Care must be taken to assess the relationship of the neoplasm to its vascular supply, the possibility of tissue invasion, and the proximity of other peripheral nerves that might be damaged during retraction, transection, and suture [68].

In a study of 123 patients with MPNST (90 sporadic and 33 NF1-associated), 28% of patients in whom surgery was attempted had negative surgical margins. These patients had a local recurrence rate of 6% as compared with 30% among the remainder with positive margins [69]. Consistent with a multivariate analysis showing that NF1 (versus sporadic) MPNST and tumor volume (≥ 200 mL) were independent predictors of inferior outcomes, the authors suggested that routine screening using MRI and/or FDG-PET in the setting of NF1 may be warranted. In an Italian case series involving 205 patients with localized MPNST who underwent surgery, positive margins were significantly associated with approximately 2-fold increased risks of cause-specific survival [hazard ratio (HR), 1.86; p = 0.021] and local recurrence (HR, 2.43; p = 0.001) [70]. A French study found that patients with R0 versus R1/2 resection had 5-year DFS rates of 45.2 and 34.3% (p = 0.0226) and 5-year OS rates of 54.6 and 41.0% (p = 0.1108), respectively [71]. Margin status was not statistically significantly associated with local recurrence or distant metastasis on multivariate analysis.

Anatomic location and tumor grade affect the surgical approach and rate of negative surgical margins. In one study [24], spinal masses were most frequently resected (83.0%) and intracranial lesions least frequently (58.1%). Although radical resection is plausible in most patients with limb MPNSTs, it may be necessary to remove the main nerve trunk (e.g., sciatic nerve).

Radiation and Chemotherapy

Multidisciplinary (multimodal) care based at an experienced sarcoma center is the cornerstone of effective management for localized disease [72]. In general, neoadjuvant chemo- and radiotherapy can be contemplated if clinical and imaging data suggest that a tumor may not be adequately resected, including preoperative planning for patients with tumors exceeding 5 cm or in the event that tumor mass needs to be rapidly decreased because the lesion is impinging on a nerve or other structure [13]. In addition to downstaging neoplasms that are borderline unresectable, neoadjuvant chemotherapy can help to ascertain chemosensitivity in patients at risk for disease dissemination, for whom doxorubicin combined with ifosfamide may be associated with improved outcomes [23]. The role of adjuvant chemotherapy is equivocal at best [73]. One study confirmed that such treatment is not effective, with the exception of epirubicin with ifosfamide, which augmented median survival by up to 75 months after local treatments, such as radiation after wide resection, amputation, or surgery after preoperative radiation [74].

Radiation

Local control of MPNST may be improved by neoadjuvant or postoperative adjuvant radiation. A multivariate analysis from a French histopathologic study of 350 patients found a 4.5-fold higher risk of local recurrence (HR, 4.50; p = 0.003), but not distant metastasis, at 5 years in patients who did not receive adjuvant radiation therapy [71]. However, tumor grade was significantly associated with metastasis but not local recurrence. A study [75] of NF1-associated and sporadic tumors affecting chiefly the extremities (58%), trunk (36%), and head and neck (6%) found an overall median OS of 46.5 months with a 5-year OS rate of 43.7%. Radiation therapy, administered to 20 of the 33 patients in this study, included brachytherapy, external beam radiation, a combination of these modalities, and proton therapy, with median total doses of 59.4 Gy for NF1-associated, and 58.5 Gy for sporadic, MPNSTs. The median OS was 33.1 months among patients with NF1-associated MPNST who received radiation, as compared with 17.4 months among those who did not. In patients with sporadic MPNST, median OS values were 51.6 and 69.4 months in radiation treated versus untreated patients, and the authors concluded that radiation therapy overall was not a significant predictor of survival.

In a retrospective analysis of 24 patients with MPNST, Kar’s group reported a 5-year DFS rate of 42% for patients with mostly deep-seated, high-grade, large (mean 10.83 cm) MPNSTs who received postoperative radiation therapy (median dose 58 Gy) compared with 0% among those who did not; respective 5-year OS values were 65 and 38% [76]. An international consensus group [77] recommended radiation for local control, to defer recurrence, and for intermediate- to high-grade lesions (and lower-grade neoplasms after marginal excisions), although this intervention is not associated with long-term life expectancy.

Chemotherapy

MPNSTs exhibit intermediate (to poor) chemosensitivity [77]. The chief role of chemotherapy (particularly anthracyclines + ifosfamide) is in the management of advanced, unresectable, or metastatic MPNST, including within palliative settings [78]. The multicenter phase 2 trial, SARC006 (NCT00304083) [79] of 48 patients with NF1-associated (n = 34) or sporadic (n = 14) MPNSTs supported the role of neoadjuvant chemotherapy in patients with high-grade or metastatic MPNST. The investigators reported nine partial responses (PRs; 5/28 [17.9%] NF1-associated and 4/9 [44.4%] sporadic) and 26 stable disease (SD; n = 22 NF1-associated and n = 4 sporadic) after two 21-day treatment cycles each of ifosfamide with doxorubicin and ifosfamide with etoposide. Neoadjuvant chemotherapy regimens supplanting doxorubicin with epirubicin may have a lower risk of cardiotoxicity. A retrospective analysis at Washington University in St. Louis found a 60% objective response rate (ORR) and 100% clinical benefit rate (CBR) in five patients with biopsy-documented MPNST who received neoadjuvant epirubicin (60 mg/m2 on days 1 and 2) and ifosfamide (1800 mg/m2 on days 1–5), with similar responses in those with either NF1-associated or sporadic MPNST [80]. Although anthracycline plus ifosfamide has clinical activity, it is also associated with a higher toxicity burden. A retrospective study [81] of 115 patients treated because of metastatic or unresectable MPNST from 2000 to 2019 found that, although doxorubicin was the most frequently used first-line treatment, there were no significant differences between the most commonly used regimens in terms of PFS, including 3.6 months for doxorubicin + dacarbazine, 2.7 months for high-dose ifosfamide, 3.1 months for etoposide + ifosfamide, 1.9 months for doxorubicin + ifosfamide, and 5.9 months for doxorubicin + cisplatin. The median OS in individuals treated with palliative intent was 15.0 months. Compared with regimens based on doxorubicin, use of gemcitabine-based regimens was associated with a significantly poorer prognosis [HR, 1.83; 95% confidence interval (CI), 1.12–3.00; p = 0.016] [81]. The median PFS was 3.9 months for anthracycline-based regimens [without local treatments (surgery or radiation)] in first line, as compared with 2.4 months in later lines (p = 0.143).

Targeted Therapies

Despite multiple cellular and molecular “leads” (biomarkers), no single driving pathogenetic event has been identified, and no particular targeted therapy has emerged as a clearly superior regimen against MPNST. Completed, small trials involving targeted therapies for mainly unresectable and/or metastatic MPNST have yielded a cumulative [response evaluation criteria in solid tumors (RECIST)] disease control rate of 22.9–34.8% (Tables 3, 4). On the basis of their analysis of data from targeted therapies in patients with MPNST (including studies summarized in Table 4), Akshintala and colleagues have suggested a threshold 4-month PFS rate of 30% for efficacy in single-arm trials [82].Table 3 Summary of clinical data on targeted therapies in MPNST

Trial	Agent (dose, schedule)	Eligibility/population characteristics	Response evaluation	N	Study determined result	
Studies of patients with MPNST	
 SARC016 [90]	Everolimus 10 mg PO daily, continuous schedule + bevacizumab 10 mg/kg IV every 2 weeks (28-day cycle)	Age ≥ 18 years; unresectable, refractory, or metastatic MPNST	WHO every 2 cycles	25	0 confirmed PR/CR, 3 SD at 4 months	
 Nishida 2020 (phase 2 IIT) [83]	Pazopanib 800 mg PO once daily continuous schedule	Grade 2–3 MPNST (by FNCLCC criteria) with locally advanced (unresectable) or metastatic lesions and/or PD within 6 months	RECIST (and modified Choi) at 12 weeks	12	CBR = 50% (Choi and RECIST)

RECIST: 1 PR, 5 SD, 6 PD

Choi: 3 PR, 3 SD, 6 PD

Median PFS = 5.4 months

Median OS = 10.6 months

	
 Al-Ezzi 2021 (retrospective) [85]	Selinexor 60 mg PO twice weekly (n = 7) or 80 mg once weekly with doxorubicin 75 mg/m2 (n = 2)	Unresectable or metastatic MPNST ECOG PS 0-2	RECIST	9	3 PR (2 on monotherapy), 4 SD	
Cumulative totala				46	0 CR

4 PR

12 SD

DCR = 34.8% (RECIST)

	
a These are not pooled datasets but rather a cumulative value of several small sample size studies, recognizing the bias of the variability of patient populations

FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer, PO orally, IIT investigator initiated trial, IV intravenously

Table 4 Summary of clinical data on targeted therapies in MPNST (including patients with MPNST in “basket” studies)

Studies including patients with MPNST	
SARC001 [86]	Imatinib 100–300 mg PO (based on BSA) twice daily, continuous	Age > 10 years, metastatic or locally advanced sarcoma, any number of therapies	Modified RECIST after Cycles 2 and 4	7	0 PR/CR, 1 SD at 4 months	
SARC009 [87]	Dasatinib 70 mg PO twice daily, continuous schedule	Age ≥ 13 years, incurable sarcoma	Choi every 2 months	14	0 PR/CR, 1 SD at 4 months	
SARC023 [89]	Ganetespib + sirolimus	Age ≥ 16 years, unresectable or refractory sarcoma (phase 1) or MPNST (phase 2)	WHO every 2 cycles	13	0 PR/CR or SD	
Albritton 2006 [88] (phase 2)	Erlotinib 150 mg PO daily in continuous daily cycles	Median age 45.3 years; 50% NF1, 19 unresectable, 18 metastatic MPNST; 15 ECOG PS 0–1	RECIST every 2 cycles	20	0 PR/CR in 19, 1 SD

Median PFS 2 months

Median OS 4 months

	
Maki 2009 (phase 2) [92]	Sorafenib 400 mg PO twice daily continuously in 28-day cycles	Age > 18 years, ECOG PS 0–2, advanced sarcoma, no recent chemotherapy or radiation therapy	RECIST every 2–3 cycles	15	0 PR/CR, 3 SD, 9 PD (12 evaluable) Median PFS = 1.7 months

Median OS = 4.9 months

PFS at 3 months = 25%

PFS at 6 months = 8%

	
Yoo 2015 (retrospective) [99]	Pazopanib 200–800 mg PO once daily	Histologically confirmed soft-tissue sarcoma	RECIST every 2 months	5	1 PR, 4 SD	
Dickson 2016 (phase 2) [93]	Alisertib 50 mg PO twice daily on days 1–7, every 21 days, with repetition of cycles dictated by neutrophil and platelet counts	Age ≥ 18 years, ECOG PS ≤ 2, histology-defined sarcoma	RECIST every 2 cycles	10	0 PR/CR

Median PFS = 13 weeks

60% progression free at 12 weeks

Median OS = 69 weeks

	
Nakamura 2016 (retrospective) [100]	Pazopanib 200–800 mg PO once daily continuous schedule	Unresectable and/or metastatic primary sarcoma of extremities/trunk	RECIST	7	0 PR/CR

3 SD

Median PFS = 7.4 weeks

	
Agulnik 2017 (phase 2) [84]	Tivozanib 1.5 mg PO for 21 days followed by 7 days off

(28-day cycles)

	Age ≥ 18 years, ECOG PS 0–1, 1–4 prior therapies for recurrent/metastatic sarcoma	RECIST every 2 cycles	5	1 PR	
Seto 2019

(retrospective) [101]

	Pazopanib 200–800 mg PO once daily	Pathologically confirmed advanced sarcoma	RECIST every 2 months	7	0 CR/PR

4 SD

	
Manji 2021 (phase 1) [91]	Pexidartinib 600–1000 mg PO daily + sirolimus 2–6 mg PO daily continuously in 28-day cycles	Unresectable pathologically confirmed sarcoma, intolerant to or progression on SOC therapy; ECOG PS 0–1	RECIST every 6 weeks	6	6 SD

Median PFS = 18.57 weeks

Median OS = 145.14 weeks

	
Cumulative totala				109	0 CR

2 PR

23 SD

DCR = 22.9% (RECIST)

	
a These are not pooled datasets but rather a cumulative value of several small sample size studies, recognizing the bias of the variability of patient populations

BSA body surface area, PO orally, SOC standard of care

Encouraging but preliminary results were reported in a Japanese phase 2 investigator-initiated trial of the small-molecule multikinase inhibitor pazopanib, an antiangiogenic compound inhibiting VEGFR and PDGFR [83]. This study of 12 patients (median age 49 years) with tumors that were mostly metastatic (91.7%), deep-seated (83.3%), and/or extremity based (58.3%); exceeded 5 cm (58.3%); and/or had Eastern Cooperative Oncology Group Scale of Performance Status (ECOG PS) of 0 or 1 who received oral pazopanib 800 mg once daily found a RECIST or Choi CBR at 12 weeks of 50% [one PR and five SDs by RECIST (and three PRs and three SDs by Choi; Table 3]. Grade 3 or 4 adverse events included neutropenia, lipase or transaminase increase, leukocyte decrease, and left-ventricular (systolic) dysfunction (leading to treatment discontinuation).

Further potentially promising outcome activity of a multikinase (VEGFR) inhibitor was revealed in a phase 2 trial of tivozanib. Among five patients ages ≥ 18 years with metastatic, locally advanced, or recurrent MPNST; 1–4 prior therapies; and ECOG PS < 2, one PR was reported [84]. (Numbers of MPNST patients with SDs were not specified.) Grade 3 adverse events included hypertension.

First-in-class oral inhibitor of exportin 1 (XPO1) selinexor also showed promise in an international retrospective study of nine patients with unresectable or metastatic MPNST. Of these patients, seven received selinexor monotherapy at 60 mg orally twice weekly and two, a combination of the XPO1 inhibitor 80 mg once weekly and doxorubicin 75 mg/m2 [85]. Three patients experienced PR (two with selinexor monotherapy), four had SD, and the remainder had progressive disease. Tumor size reductions ranged from 10% to 56% at the time of best response in seven patients, and the mean (range) duration of disease control was 4.5 (2.5–13.5) months [85]. Adverse events included fatigue, anorexia, and biochemical or hematologic abnormalities, with four of nine patients requiring dose reductions because of intolerable AEs .

No objective responses were observed after treatment of MPNST via a wide range of targeted therapeutic mechanisms, including the BCR-ABL1 TKIs imatinib (in SARC001 [86]; one patient had SD at 2 and 4 months) and dasatinib [87] (number of SDs in MPNST not reported); the EGFR TKI erlotinib [88] (number of SDs not reported); an mTOR inhibitor combined with Hsp90 inhibitor ganetespib (in SARC023 [89]) anti-VEGF monoclonal antibody bevacizumab plus everolimus [in SARC016 [90]; according to World Health Organization (WHO) criteria, the best response was SD in 3/25 (12%) patients] or multikinase (CSF-1R) inhibitor pexidartinib with sirolimus [91] (6 SDs); multikinase (RAF/MEK/ERK/VEGFR/PDGFR) inhibitor sorafenib [92] [3/12 (25%) MPNST patients had SD; the median PFS was 1.7 months, and the median OS 4.9 months], and AURKA inhibitor alisertib (no SDs reported; the median PFS was 13 weeks) [93]. Given the high incidence of MTAP deletion in MPNST, PRMT5 inhibitors [e.g., TNG908 (NCT05275478), TNG462 (NCT05732831)] are emerging as potential targeted therapies and have demonstrated antiproliferative and antitumor effects in preclinical models of MTAP-deleted MPNST [94].

Ongoing clinical trials in MPNST are summarized in Table 5. Many are pursuing combinatorial approaches directed toward multiple signaling pathways. Signaling pathways of interest that are not targeted in the aforementioned trials (summarized in Tables 3, 4) include EZH2 with tazemetostat (NCT04917042), immune checkpoints with PD-1 inhibitor nivolumab and CTLA4 inhibitor ipilimumab (NCT04465643), and c-Met with AL2846, as well as MDM2-p53 and PD-1 with alrizomadlin and pembrolizumab (NCT03611868). Oncolytic viral approaches are also being investigated (NCT02700230).

Limitations

Given the overall low incidence of MPNST, the limitations of this review (and the field in general) center on the inclusion of retrospective evidence (e.g., single-center case series). Additional high-quality, prospective trials (and/or observational registries) involving larger numbers of patients with MPNST are warranted to evaluate the relative merits and pitfalls of distinct therapeutic strategies and better understand the roles of radiation and chemotherapy in MPNST management. Finally, the range of benchmark DCR values for targeted therapies in MPNST (22.9–34.8%) that we report on the basis of our literature review is not representative of pooled datasets but rather a cumulative value of several small sample size studies, recognizing the bias of the variability of patient populations (Table 3, 4).Table 5 Summary of ongoing clinical trials of targeted therapies for MPNST

Treatment	Status	CT.gov identifier	Sponsor	
Membrane, cytoplasmic, and nuclear targeted therapies	
SARC023: sirolimus + Hsp90 inhibitor ganetespib in MPNST [89]	Phase 1–2 completed	NCT02008877	Synta Pharmaceuticals	
Sirolimus + multikinase inhibitor pexidartinib in unresectable sarcoma and MPNST	Phase 1–2 not recruiting	NCT02584647	Daiichi Sankyo	
Multikinase inhibitor AL2846 in NF1 or MPNST	Phase 1–2 recruiting	NCT05011019	Chia Tai Tianqing Pharmaceutical Group	
EGFR TKI erlotinib in unresectable and metastatic MPNST [88]	Phase 2 completed	NCT00068367	SWOG/NCI	
EZH2 inhibitor tazemetostat in MPNST	Phase 2 recruiting	NCT04917042	Epizyme	
SARC016: mTOR inhibitor everolimus + bevacizumab for refractory MPNST [90]	Phase 2 completed	NCT01661283	Novartis, Genentech	
SARC031: mTOR inhibitor sirolimus + MEK inhibitor selumetinib (AZD6244) in MPNST	Phase 2 active (not recruiting)	NCT03433183	AstraZeneca	
MDM2-p53 inhibitor alrizomadlin (APG-115) + PD-1 inhibitor pembrolizumab in MPNST	Phase 1b/2 active (recruiting)	NCT03611868	Ascentage	
A study of ASTX727 (cedazuridine + decitabine targeting PRC2-mutant cells) in people with MPNST	Phase 1–2 recruiting	NCT04872543	Memorial Sloan Kettering Cancer Center	
Immunotherapy and oncolytic viruses	
Neoadjuvant nivolumab + ipilimumab for newly diagnosed MPNST	Phase 1 recruiting	NCT04465643	Bristol Myers Squibb	
Oncolytic measles virus encoding thyroidal sodium iodide symporter vaccine for recurrent or unresectable MPNST	Phase 1 recruiting	NCT02700230	Mayo Clinic/NCI	
CT.gov ClinicalTrials.gov, SARC Sarcoma Alliance for Research through Collaboration

Summary

Malignant peripheral nerve sheath tumors are rare, aggressive soft-tissue sarcomas with a tendency for local recurrence and metastasis and are recognized to have among the poorest prognoses of all sarcomas. Although surgical resection is potentially curative in localized disease, overall outcomes with this therapeutic modality and others are suboptimal, establishing an urgent unmet medical need. Advances in genetics and molecular biology have unveiled a range of potentially pathologic signaling pathways, yet further research is warranted to unravel the complex pathogenesis of this condition, no single druggable target has emerged, and combinatorial approaches addressing multiple pathways are hallmarks of ongoing clinical trials. To date, the prognosis of this disease, which affects children, young adults, and mid-life adults in their prime is very poor, with a maximum (after surgery with curative intent) median OS of 95.8 months and median PFS of 26.3 months (< 5 and < 2 months, respectively, in unresectable MPNST) [95], which have not improved over the last 20 years, and a reliance on only toxic chemotherapy without significant progress in targeted therapy therapeutic options, which are dearly needed.

Declarations

Funding

This review was supported by Ascentage Pharma Group Corp. Ltd. (Hong Kong). The authors were not compensated for their roles in drafting and reviewing the manuscript, had free and unfettered access to all data (published references), and had full autonomy over all decisions concerning content. Stephen W. Gutkin with Ascentage Pharma Group Inc. provided further substantive input in manuscript research and preparation.

Conflict of interest

N.S. reports current clinical trial research funding/grant support through her institution from AstraZeneca, Ascentage, Deciphera, Cogent, Boehringer Ingelheim, IDRX, Ningo Newbay, and Bayer. She reports serving as an Advisory Board consultant (last 2 years) for Aadi Biosciences, Adaptimmune, Bayer, Deciphera, and Boehringer Ingelheim. B.P. and R.W. report being full-time employees of Ascentage Pharma Group Inc. and shareholders in the parent, Ascentage Pharma Group International, B.V.T. reports a research grant from Polaris; royalties of licenses from Accuronix Therapeutics; consulting relationships with Aadi Biosciences, Acuta Capital Partners, LLC, Advenchen Laboratories, Bayer, Boxer Capital LLC, Cytokinetics Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals, EcoR1, Kronos Bio, Inc., Putnam, Race Oncology, Salarius Pharmaceuticals, Inc., and Sonata Therapeutics, Inc.; payments or honoraria from Iterion Therapeutics, Inc., and Total Health Conference; support for attending meetings and/or travel from Adaptimmune, Advnchen, Kronos Bio, and Polaris; patents on ALEXT3102 and the use of ME1 as a biomarker; participation on Data Safety Monitoring or Advisory Boards for Aadi Biosciences, Agenus, Apexigen, Inc., Bayer US Medical Affairs Oncology, Boehringer Ingelheim, Curis, Daiichi Sankyo, Epizyme, PTC Therapeutics, and Regeneron Pharmaceuticals; and leadership or fiduciary roles in other board, society, committee, or advocacy group with Polaris (nonpaid safety monitoring board). A.C.H. reports royalties or licenses from Boehringer Ingelheim GmbH and Deutsches Krebsforschungszentrum (licensing/product development agreements); consulting fees from Springworks; payments or honoraria from the American Physician Institute for Advanced Professional Studies and Empartners; support for attending meetings and/or travel from Alexion Pharmaceuticals, Inc.; and participation on Data Safety Monitoring or Advisory Boards from Alexion Pharmaceuticals and AstraZeneca Pharmaceuticals LP.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

All authors.

Availability of data and material

All data originated from published references.

Code availability

Not applicable.

Author contributions

All authors played a role in conceiving the review; acquiring and analyzing data; drafting, reviewing, revising, and approving the manuscript; and the decision to submit it for publication. No datasets were generated or analyzed during the current study.
==== Refs
References

1. Martin E Lamba N Flucke UE Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside Crit Rev Oncol Hematol 2019 138 223 232 10.1016/j.critrevonc.2019.04.007 31092379
Martin E, Lamba N, Flucke UE, et al. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside. Crit Rev Oncol Hematol. 2019;138:223–32.31092379 10.1016/j.critrevonc.2019.04.007
2. Xu Y Xu G Liu Z Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors Acta Neurochir (Wien) 2021 163 2 521 529 10.1007/s00701-020-04647-5 33219865
Xu Y, Xu G, Liu Z, et al. Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors. Acta Neurochir (Wien). 2021;163(2):521–9.33219865 10.1007/s00701-020-04647-5
3. Cortes-Ciriano I Steele CD Piculell K Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA Cancer Discov 2023 13 3 654 671 10.1158/2159-8290.CD-22-0786 36598417
Cortes-Ciriano I, Steele CD, Piculell K, et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13(3):654–71.36598417 10.1158/2159-8290.CD-22-0786
4. Kim A Stewart DR Reilly KM Viskochil D Miettinen MM Widemann BC Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies Sarcoma 2017 2017 7429697 10.1155/2017/7429697 28592921
Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017;2017:7429697.28592921 10.1155/2017/7429697
5. Jack AS Huie CJ Jacques LG Guedes F Zager EL Garozzo D Rasulic L Socolovsky M Epidemiology of peripheral nerve sheath tumors Diagnostic assessment and treatment of peripheral nerve tumors 2021 Cham Springer Nature 3 16
Jack AS, Huie CJ, Jacques LG. Epidemiology of peripheral nerve sheath tumors. In: Guedes F, Zager EL, Garozzo D, Rasulic L, Socolovsky M, editors. Diagnostic assessment and treatment of peripheral nerve tumors. Cham, Switzerland: Springer Nature; 2021. p. 3–16.
6. American Cancer Society. Key statistics for soft tissue sarcomas. 2023. https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html. Accessed 7 June 2024.
7. Meyer M Seetharam M First-line therapy for metastatic soft tissue sarcoma Curr Ther Opin Oncol 2019 20 6
Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Ther Opin Oncol. 2019;20:6.
8. Watson KL Al Sannaa GA Kivlin CM Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors J Neurosurg 2017 126 1 319 329 10.3171/2015.12.JNS152443 27035165
Watson KL, Al Sannaa GA, Kivlin CM, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg. 2017;126(1):319–29.27035165 10.3171/2015.12.JNS152443
9. Grobmyer SR Reith JD Shahlaee A Bush CH Hochwald SN Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations J Surg Oncol 2008 97 4 340 349 10.1002/jso.20971 18286466
Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97(4):340–9.18286466 10.1002/jso.20971
10. Ducatman BS Scheithauer BW Postirradiation neurofibrosarcoma Cancer 1983 51 6 1028 1033 10.1002/1097-0142(19830315)51:6<1028::AID-CNCR2820510610>3.0.CO;2-3 6821867
Ducatman BS, Scheithauer BW. Postirradiation neurofibrosarcoma. Cancer. 1983;51(6):1028–33.6821867 10.1002/1097-0142(19830315)51:6<1028::AID-CNCR2820510610>3.0.CO;2-3
11. Ducatman BS Scheithauer BW Piepgras DG Reiman HM Ilstrup DM Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases Cancer 1986 57 10 2006 2021 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6 3082508
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–21.3082508 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
12. Katz D Lazar A Lev D Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways Expert Rev Mol Med 2009 11 e30 10.1017/S1462399409001227 19835664
Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009;11: e30.19835664 10.1017/S1462399409001227
13. Czarnecka AM Malignant peripheral nerve sheath tumour (MPNST) Oncol Clin Pract 2018 14 6 364 376 10.5603/OCP.2018.0050
Czarnecka AM. Malignant peripheral nerve sheath tumour (MPNST). Oncol Clin Pract. 2018;14(6):364–76.10.5603/OCP.2018.0050
14. Friedrich R Hartmann M Mautner V-F Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children Anticancer Res 2007 27 1957 1960 17649804
Friedrich R, Hartmann M, Mautner V-F. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. Anticancer Res. 2007;27:1957–60.17649804
15. Noreña-Rengifo BD Cadavid-Alvarez LM Gil-Serrano PE Varela-Aguirre JV Malignant peripheral nerve sheath tumor in a child Radiol Case Reports 2021 16 145 151 10.1016/j.radcr.2020.10.028
Noreña-Rengifo BD, Cadavid-Alvarez LM, Gil-Serrano PE, Varela-Aguirre JV. Malignant peripheral nerve sheath tumor in a child. Radiol Case Reports. 2021;16:145–51.10.1016/j.radcr.2020.10.028
16. Ferrari A Bisogno G Macaluso A Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1 Cancer 2007 109 7 1406 1412 10.1002/cncr.22533 17330850
Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007;109(7):1406–12.17330850 10.1002/cncr.22533
17. Landry JP Schertz KL Chiang YJ Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020 JAMA Netw Open 2021 4 3 e210945 10.1001/jamanetworkopen.2021.0945 33734413
Landry JP, Schertz KL, Chiang YJ, et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open. 2021;4(3): e210945.33734413 10.1001/jamanetworkopen.2021.0945
18. Hwang IK Hahn SM Kim HS Outcomes of treatment for malignant peripheral nerve sheath tumors: different clinical features associated with neurofibromatosis type 1 Cancer Res Treat 2017 49 3 717 726 10.4143/crt.2016.271 28052660
Hwang IK, Hahn SM, Kim HS, et al. Outcomes of treatment for malignant peripheral nerve sheath tumors: different clinical features associated with neurofibromatosis type 1. Cancer Res Treat. 2017;49(3):717–26.28052660 10.4143/crt.2016.271
19. Kolberg M Holand M Agesen TH Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1 Neuro Oncol 2013 15 2 135 147 10.1093/neuonc/nos287 23161774
Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(2):135–47.23161774 10.1093/neuonc/nos287
20. Stucky CC Johnson KN Gray RJ Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience Ann Surg Oncol 2012 19 3 878 885 10.1245/s10434-011-1978-7 21861229
Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–85.21861229 10.1245/s10434-011-1978-7
21. Cai Z Tang X Liang H Yang R Yan T Guo W Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis World J Surg Oncol 2020 18 1 257 10.1186/s12957-020-02036-x 32998743
Cai Z, Tang X, Liang H, Yang R, Yan T, Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):257.32998743 10.1186/s12957-020-02036-x
22. Bishop JA Thompson LD Cardesa A Rhabdomyoblastic differentiation in head and neck malignancies other than rhabdomyosarcoma Head Neck Pathol 2015 9 4 507 518 10.1007/s12105-015-0624-2 25757816
Bishop JA, Thompson LD, Cardesa A, et al. Rhabdomyoblastic differentiation in head and neck malignancies other than rhabdomyosarcoma. Head Neck Pathol. 2015;9(4):507–18.25757816 10.1007/s12105-015-0624-2
23. James AW Shurell E Singh A Dry SM Eilber FC Malignant peripheral nerve sheath tumor Surg Oncol Clin N Am 2016 25 4 789 802 10.1016/j.soc.2016.05.009 27591499
James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor. Surg Oncol Clin N Am. 2016;25(4):789–802.27591499 10.1016/j.soc.2016.05.009
24. Martin E Muskens IS Coert JH Smith TR Broekman MLD Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature Neurooncol Pract 2019 6 2 134 143 31386019
Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature. Neurooncol Pract. 2019;6(2):134–43.31386019
25. Arshi A Tajudeen BA St JM Malignant peripheral nerve sheath tumors of the head and neck: demographics, clinicopathologic features, management, and treatment outcomes Oral Oncol 2015 51 12 1088 1094 10.1016/j.oraloncology.2015.08.012 26442813
Arshi A, Tajudeen BA, St John M. Malignant peripheral nerve sheath tumors of the head and neck: demographics, clinicopathologic features, management, and treatment outcomes. Oral Oncol. 2015;51(12):1088–94.26442813 10.1016/j.oraloncology.2015.08.012
26. Williams LA Moertel CL Richardson M Marcotte EL Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors J Neurooncol 2020 147 3 701 709 10.1007/s11060-020-03478-9 32239432
Williams LA, Moertel CL, Richardson M, Marcotte EL. Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors. J Neurooncol. 2020;147(3):701–9.32239432 10.1007/s11060-020-03478-9
27. Dehner C, Moon CI, Zhang X, et al. Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight. 2021;6(6):e146351.
28. Mechtersheimer G Otaño-Joos M Ohl S Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization Genes Chromosomes Cancer 1999 25 4 362 369 10.1002/(SICI)1098-2264(199908)25:4<362::AID-GCC8>3.0.CO;2-Q 10398430
Mechtersheimer G, Otaño-Joos M, Ohl S, et al. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer. 1999;25(4):362–9.10398430 10.1002/(SICI)1098-2264(199908)25:4<362::AID-GCC8>3.0.CO;2-Q
29. Watson AL Anderson LK Greeley AD Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of Schwann cell tumors reduces tumor grade and multiplicity Oncotarget 2014 5 6 1502 1514 10.18632/oncotarget.1609 24681606
Watson AL, Anderson LK, Greeley AD, et al. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014;5(6):1502–14.24681606 10.18632/oncotarget.1609
30. Kim AR, Ballman K, Wolters P, et al. SARC031: a phase 2 trial of selumetinib and sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. Presented at CTOS (Connective Tissue Oncology Society). Vancouver, Canada. November 17, 2022.
31. Hirbe AC Dahiya S Friedmann-Morvinski D Verma IM Clapp DW Gutmann DH Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation Oncotarget 2016 7 7 7403 7414 10.18632/oncotarget.7232 26859681
Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. 2016;7(7):7403–14.26859681 10.18632/oncotarget.7232
32. Cichowski K Shih TS Schmitt E Mouse models of tumor development in neurofibromatosis type 1 Science 1999 286 5447 2172 2176 10.1126/science.286.5447.2172 10591652
Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172–6.10591652 10.1126/science.286.5447.2172
33. Dodd RD Mito JK Eward WC NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition Mol Cancer Ther 2013 12 9 1906 1917 10.1158/1535-7163.MCT-13-0189 23858101
Dodd RD, Mito JK, Eward WC, et al. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther. 2013;12(9):1906–17.23858101 10.1158/1535-7163.MCT-13-0189
34. Gregorian C Nakashima J Dry SM PTEN dosage is essential for neurofibroma development and malignant transformation Proc Natl Acad Sci USA 2009 106 46 19479 19484 10.1073/pnas.0910398106 19846776
Gregorian C, Nakashima J, Dry SM, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA. 2009;106(46):19479–84.19846776 10.1073/pnas.0910398106
35. King D Yang G Thompson MA Hiebert SW Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype Oncogene 2002 21 32 4978 4982 10.1038/sj.onc.1205632 12118376
King D, Yang G, Thompson MA, Hiebert SW. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype. Oncogene. 2002;21(32):4978–82.12118376 10.1038/sj.onc.1205632
36. Vogel KS Klesse LJ Velasco-Miguel S Meyers K Rushing EJ Parada LF Mouse tumor model for neurofibromatosis type 1 Science 1999 286 5447 2176 2179 10.1126/science.286.5447.2176 10591653
Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science. 1999;286(5447):2176–9.10591653 10.1126/science.286.5447.2176
37. Wu J Patmore DM Jousma E EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors Oncogene 2014 33 2 173 180 10.1038/onc.2012.579 23318430
Wu J, Patmore DM, Jousma E, et al. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 2014;33(2):173–80.23318430 10.1038/onc.2012.579
38. Rhodes SD He Y Smith A Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation Hum Mol Genet 2019 28 16 2752 2762 10.1093/hmg/ddz095 31091306
Rhodes SD, He Y, Smith A, et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum Mol Genet. 2019;28(16):2752–62.31091306 10.1093/hmg/ddz095
39. Carroll SL Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms Acta Neuropathol 2012 123 3 321 348 10.1007/s00401-011-0928-6 22160322
Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012;123(3):321–48.22160322 10.1007/s00401-011-0928-6
40. Holtkamp N Malzer E Zietsch J EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy Neuro Oncol 2008 10 6 946 957 10.1215/15228517-2008-053 18650488
Holtkamp N, Malzer E, Zietsch J, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol. 2008;10(6):946–57.18650488 10.1215/15228517-2008-053
41. Keng VW Watson AL Rahrmann EP Conditional inactivation of PTEN with EGFR overexpression in Schwann cells models sporadic MPNST Sarcoma 2012 2012 620834 10.1155/2012/620834 23319880
Keng VW, Watson AL, Rahrmann EP, et al. Conditional inactivation of PTEN with EGFR overexpression in schwann cells models sporadic MPNST. Sarcoma. 2012;2012: 620834.23319880 10.1155/2012/620834
42. Nielsen GP Stemmer-Rachamimov AO Ino Y Moller MB Rosenberg AE Louis DN Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation Am J Pathol 1999 155 6 1879 1884 10.1016/S0002-9440(10)65507-1 10595918
Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155(6):1879–84.10595918 10.1016/S0002-9440(10)65507-1
43. Widemann BC Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors Curr Oncol Rep 2009 11 4 322 328 10.1007/s11912-009-0045-z 19508838
Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11(4):322–8.19508838 10.1007/s11912-009-0045-z
44. Lee W Teckie S Wiesner T PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors Nat Genet 2014 46 11 1227 1232 10.1038/ng.3095 25240281
Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227–32.25240281 10.1038/ng.3095
45. Brockman QR, Scherer A, McGivney GR, et al. PRC2 loss drives MPNST metastasis and matrix remodeling. JCI Insight. 2022;7(20):e157502.
46. Zhang M Wang Y Jones S Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors Nat Genet 2014 46 11 1170 1172 10.1038/ng.3116 25305755
Zhang M, Wang Y, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1170–2.25305755 10.1038/ng.3116
47. Zhang P Garnett J Creighton CJ EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis J Pathol 2014 232 3 308 318 10.1002/path.4294 24132643
Zhang P, Garnett J, Creighton CJ, et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol. 2014;232(3):308–18.24132643 10.1002/path.4294
48. Zhang P Yang X Ma X Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway Mol Cancer 2015 14 55 10.1186/s12943-015-0325-1 25890085
Zhang P, Yang X, Ma X, et al. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015;14:55.25890085 10.1186/s12943-015-0325-1
49. Patel AV Eaves D Jessen WJ Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target Clin Cancer Res 2012 18 18 5020 5030 10.1158/1078-0432.CCR-12-1072 22811580
Patel AV, Eaves D, Jessen WJ, et al. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 2012;18(18):5020–30.22811580 10.1158/1078-0432.CCR-12-1072
50. Borcherding DC Amin NV He K MEK inhibition synergizes with TYK2 inhibitors in NF1-associated malignant peripheral nerve sheath tumors Clin Cancer Res 2023 29 8 1592 1604 10.1158/1078-0432.CCR-22-3722 36799629
Borcherding DC, Amin NV, He K, et al. MEK inhibition synergizes with TYK2 inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Clin Cancer Res. 2023;29(8):1592–604.36799629 10.1158/1078-0432.CCR-22-3722
51. Landers SM Bhalla AD Ma X AXL inhibition enhances MEK inhibitor sensitivity in malignant peripheral nerve sheath tumors J Cancer Sci Clin Ther 2020 4 4 511 525 10.26502/jcsct.5079091 33283192
Landers SM, Bhalla AD, Ma X, et al. AXL inhibition enhances MEK inhibitor sensitivity in malignant peripheral nerve sheath tumors. J Cancer Sci Clin Ther. 2020;4(4):511–25.33283192 10.26502/jcsct.5079091
52. Yang J Ylipaa A Sun Y Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment Clin Cancer Res 2011 17 24 7563 7573 10.1158/1078-0432.CCR-11-1707 22042973
Yang J, Ylipaa A, Sun Y, et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res. 2011;17(24):7563–73.22042973 10.1158/1078-0432.CCR-11-1707
53. Ki DH He S Rodig S Look AT Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors Oncogene 2017 36 8 1058 1068 10.1038/onc.2016.269 27477693
Ki DH, He S, Rodig S, Look AT. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Oncogene. 2017;36(8):1058–68.27477693 10.1038/onc.2016.269
54. Mo W Chen J Patel A CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors Cell 2013 152 5 1077 1090 10.1016/j.cell.2013.01.053 23434321
Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013;152(5):1077–90.23434321 10.1016/j.cell.2013.01.053
55. Mrowczynski OD, Payne RA, Bourcier AJ, et al. Targeting IL-13Rα2 for effective treatment of malignant peripheral nerve sheath tumors in mouse models. J Neurosurg. 2018;130(5):1369-79.
56. Fukushima S Endo M Matsumoto Y Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor PLoS ONE 2017 12 5 e0178064 10.1371/journal.pone.0178064 28558056
Fukushima S, Endo M, Matsumoto Y, et al. Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. PLoS ONE. 2017;12(5): e0178064.28558056 10.1371/journal.pone.0178064
57. Rad E Dodd K Thomas L Upadhyaya M Tee A STAT3 and HIF1α signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors Mol Cancer Res 2015 13 7 1149 1160 10.1158/1541-7786.MCR-14-0182 25833823
Rad E, Dodd K, Thomas L, Upadhyaya M, Tee A. STAT3 and HIF1α signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Mol Cancer Res. 2015;13(7):1149–60.25833823 10.1158/1541-7786.MCR-14-0182
58. Shurell E Singh AS Crompton JG Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes Oncotarget 2016 7 39 64300 64308 10.18632/oncotarget.11734 27588404
Shurell E, Singh AS, Crompton JG, et al. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget. 2016;7(39):64300–8.27588404 10.18632/oncotarget.11734
59. Dancsok AR Gao D Lee AF Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas Oncoimmunology 2020 9 1 1747340 10.1080/2162402X.2020.1747340 32313727
Dancsok AR, Gao D, Lee AF, et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. 2020;9(1):1747340.32313727 10.1080/2162402X.2020.1747340
60. Friedrich RE Beer C Glatzel M Hagel C Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neur1fibromatosis type 1 Anticancer Res 2015 35 1 137 144 25550544
Friedrich RE, Beer C, Glatzel M, Hagel C. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1. Anticancer Res. 2015;35(1):137–44.25550544
61. Thomas LE Winston J Rad E Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours Hum Genomics 2015 9 1 3 10.1186/s40246-015-0025-3 25884485
Thomas LE, Winston J, Rad E, et al. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Hum Genomics. 2015;9(1):3.25884485 10.1186/s40246-015-0025-3
62. Wu LMN Zhang F Rao R Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy Sci Adv 2022 8 44 eabo5442 10.1126/sciadv.abo5442 36322658
Wu LMN, Zhang F, Rao R, et al. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv. 2022;8(44):eabo5442.36322658 10.1126/sciadv.abo5442
63. Benz MR Czernin J Dry SM Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign Cancer 2010 116 2 451 458 10.1002/cncr.24755 19924789
Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116(2):451–8.19924789 10.1002/cncr.24755
64. Ahlawat S Blakeley JO Rodriguez FJ Fayad LM Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1 Neurology 2019 93 11 e1076 e1084 10.1212/WNL.0000000000008092 31395668
Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 2019;93(11):e1076–84.31395668 10.1212/WNL.0000000000008092
65. Koike H Nishida Y Ito S Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of benign from malignant peripheral nerve sheath tumors World Neurosurg 2022 157 e207 e214 10.1016/j.wneu.2021.09.130 34624521
Koike H, Nishida Y, Ito S, et al. Diffusion-weighted magnetic resonance imaging improves the accuracy of differentiation of benign from malignant peripheral nerve sheath tumors. World Neurosurg. 2022;157:e207–14.34624521 10.1016/j.wneu.2021.09.130
66. Reinert CP Schuhmann MU Bender B Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI Eur J Nucl Med Mol Imaging 2019 46 3 776 787 10.1007/s00259-018-4227-5 30535768
Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46(3):776–87.30535768 10.1007/s00259-018-4227-5
67. Szymanski JJ Sundby RT Jones PA Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study PLoS Med 2021 18 8 e1003734 10.1371/journal.pmed.1003734 34464388
Szymanski JJ, Sundby RT, Jones PA, et al. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study. PLoS Med. 2021;18(8): e1003734.34464388 10.1371/journal.pmed.1003734
68. Guedes F Sanches GE Bulhões S Siquara-de-Sousa AC Soares Gonçalves Cunha K Guedes F Zager EL Garozzo D Rasulic L Socolovsky M Malignant peripheral nerve sheath tumors Diagnositc assessment and treatment of peripheral nerve tumors 2021 Springer Nature Cham 193 222
Guedes F, Sanches GE, Bulhões S, Siquara-de-Sousa AC, Soares Gonçalves Cunha K. Malignant peripheral nerve sheath tumors. In: Guedes F, Zager EL, Garozzo D, Rasulic L, Socolovsky M, editors. Diagnostic assessment and treatment of peripheral nerve tumors, Cham, Switzerland: Springer Nature; 2021. p. 193–222.
69. Porter DE Prasad V Foster L Dall GF Birch R Grimer RJ Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours Sarcoma 2009 2009 756395 10.1155/2009/756395 19360115
Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;2009: 756395.19360115 10.1155/2009/756395
70. Anghileri M Miceli R Fiore M Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution Cancer 2006 107 1065 1074 10.1002/cncr.22098 16881077
Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065–74.16881077 10.1002/cncr.22098
71. Le Guellec S Decouvelaere AV Filleron T Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group Database Am J Surg Pathol 2016 40 7 896 908 10.1097/PAS.0000000000000655 27158754
Le Guellec S, Decouvelaere AV, Filleron T, et al. Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group Database. Am J Surg Pathol. 2016;40(7):896–908.27158754 10.1097/PAS.0000000000000655
72. Prudner BC Ball T Rathore R Hirbe AC Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives Neurooncol Adv 2020 2 Suppl 1 i40 i49 32642731
Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: current practice and future perspectives. Neurooncol Adv. 2020;2(Suppl 1):i40–9.32642731
73. Yao C Zhou J Dong Y Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management Cancers 2023 15 1077 10.3390/cancers15041077 36831419
Yao C, Zhou J, Dong Y, et al. Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management. Cancers. 2023;15:1077.36831419 10.3390/cancers15041077
74. Furstaci S Gherlinzoni F De Paoli A Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative Trial J Clin Oncol 2001 19 1238 1247 10.1200/JCO.2001.19.5.1238 11230464
Furstaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative Trial. J Clin Oncol. 2001;19:1238–47.11230464 10.1200/JCO.2001.19.5.1238
75. Kahn J Gillespie A Tsokos M Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors Front Oncol 2014 4 324 10.3389/fonc.2014.00324 25452937
Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324.25452937 10.3389/fonc.2014.00324
76. Kar M Deo SV Shukla NK Malignant peripheral nerve sheath tumors (MPNST)—clinicopathological study and treatment outcome of twenty-four cases World J Surg Oncol 2006 4 55 10.1186/1477-7819-4-55 16923196
Kar M, Deo SV, Shukla NK, et al. Malignant peripheral nerve sheath tumors (MPNST)—clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol. 2006;4:55.16923196 10.1186/1477-7819-4-55
77. Ferner RE Gutmann DH International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis Cancer Res 2002 62 5 1573 1577 11894862
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573–7.11894862
78. Zehou O Fabre E Zelek L Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review Orphanet J Rare Dis 2013 8 127 10.1186/1750-1172-8-127 23972085
Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127.23972085 10.1186/1750-1172-8-127
79. Higham CS Steinberg SM Dombi E SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis Type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors Sarcoma 2017 2017 8685638 10.1155/2017/8685638 29138631
Higham CS, Steinberg SM, Dombi E, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma. 2017;2017:8685638.29138631 10.1155/2017/8685638
80. Hirbe AC Cosper PF Dahiya S Van Tine BA Neoadjuvant ifosfamide and epirubicin in the treatment of malignant peripheral nerve sheath tumors Sarcoma 2017 2017 3761292 10.1155/2017/3761292 28546782
Hirbe AC, Cosper PF, Dahiya S, Van Tine BA. Neoadjuvant ifosfamide and epirubicin in the treatment of malignant peripheral nerve sheath tumors. Sarcoma. 2017;2017:3761292.28546782 10.1155/2017/3761292
81. Sobczuk P Teterycz P Czarnecka AM Systemic treatment for advanced and metastatic malignant peripheral nerve sheath tumors—a sarcoma reference center experience J Clin Med 2020 9 3157 10.3390/jcm9103157 33003503
Sobczuk P, Teterycz P, Czarnecka AM, et al. Systemic treatment for advanced and metastatic malignant peripheral nerve sheath tumors—a sarcoma reference center experience. J Clin Med. 2020;9:3157.33003503 10.3390/jcm9103157
82. Akshintala S Mallory NC Lu Y Outcome of patients with malignant peripheral nerve sheath tumors enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) phase II trials Oncologist 2023 28 5 453 459 10.1093/oncolo/oyac272 36724001
Akshintala S, Mallory NC, Lu Y, et al. Outcome of patients with malignant peripheral nerve sheath tumors enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) phase II trials. Oncologist. 2023;28(5):453–9.36724001 10.1093/oncolo/oyac272
83. Nishida Y Urakawa H Nakayama R Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors Int J Cancer 2021 148 1 140 149 10.1002/ijc.33201 32638374
Nishida Y, Urakawa H, Nakayama R, et al. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. Int J Cancer. 2021;148(1):140–9.32638374 10.1002/ijc.33201
84. Agulnik M Costa RLB Milhem M A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas Ann Oncol 2017 28 1 121 127 10.1093/annonc/mdw444 27771610
Agulnik M, Costa RLB, Milhem M, et al. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017;28(1):121–7.27771610 10.1093/annonc/mdw444
85. Al-Ezzi E Gounder M Watson G Selinexor, a first in class, nuclear export inhibitor for the treatment of advanced malignant peripheral nerve sheath tumor Oncologist 2021 26 4 e710 e714 10.1002/onco.13692 33512749
Al-Ezzi E, Gounder M, Watson G, et al. Selinexor, a first in class, nuclear export inhibitor for the treatment of advanced malignant peripheral nerve sheath tumor. Oncologist. 2021;26(4):e710–4.33512749 10.1002/onco.13692
86. Chugh R Wathen JK Maki RG Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model J Clin Oncol 2009 27 19 3148 3153 10.1200/JCO.2008.20.5054 19451433
Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.19451433 10.1200/JCO.2008.20.5054
87. Schuetze SM Wathen JK Lucas DR SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma Cancer 2016 122 6 868 874 10.1002/cncr.29858 26710211
Schuetze SM, Wathen JK, Lucas DR, et al. SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016;122(6):868–74.26710211 10.1002/cncr.29858
88. Albritton KH Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). 2006 ASCO abstract J Clin Oncol 2006 24 18 9518 10.1200/jco.2006.24.18_suppl.9518
Albritton KH. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). 2006 ASCO abstract. J Clin Oncol. 2006;24(18):9518.10.1200/jco.2006.24.18_suppl.9518
89. Kim A Lu Y Okuno SH Targeting refractory sarcomas and malignant peripheral nerve sheath tumors in a phase I/II study of sirolimus in combination with ganetespib (SARC023) Sarcoma 2020 2020 5784876 10.1155/2020/5784876 32089640
Kim A, Lu Y, Okuno SH, et al. Targeting refractory sarcomas and malignant peripheral nerve sheath tumors in a phase I/II study of sirolimus in combination with ganetespib (SARC023). Sarcoma. 2020;2020:5784876.32089640 10.1155/2020/5784876
90. Widemann BC Lu Y Reinke D Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016) Sarcoma 2019 2019 7656747 10.1155/2019/7656747 31427883
Widemann BC, Lu Y, Reinke D, et al. Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016). Sarcoma. 2019;2019:7656747.31427883 10.1155/2019/7656747
91. Manji GA Van Tine BA Lee SM A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors Clin Cancer Res 2021 27 20 5519 5527 10.1158/1078-0432.CCR-21-1779 34321280
Manji GA, Van Tine BA, Lee SM, et al. A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors. Clin Cancer Res. 2021;27(20):5519–27.34321280 10.1158/1078-0432.CCR-21-1779
92. Maki RG D'Adamo DR Keohan ML Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol 2009 27 19 3133 3140 10.1200/JCO.2008.20.4495 19451436
Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–40.19451436 10.1200/JCO.2008.20.4495
93. Dickson MA Mahoney MR Tap WD Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma Ann Oncol 2016 27 10 1855 1860 10.1093/annonc/mdw281 27502708
Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016;27(10):1855–60.27502708 10.1093/annonc/mdw281
94. Borcherding D Zhang X Zhang M MTA-cooperative PRMT5 inhibitors are efficacious in MTAP-deleted malignant peripheral nerve sheath tumor models Neuro-Oncol 2023 25 Suppl 5 v238 10.1093/neuonc/noad179.0916
Borcherding D, Zhang X, Zhang M, et al. MTA-cooperative PRMT5 inhibitors are efficacious in MTAP-deleted malignant peripheral nerve sheath tumor models. Neuro-Oncol. 2023;25(Suppl 5): v238.10.1093/neuonc/noad179.0916
95. Valentin T Le Cesne A Ray-Coquard I Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO) Eur J Cancer 2016 56 77 84 10.1016/j.ejca.2015.12.015 26824706
Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.26824706 10.1016/j.ejca.2015.12.015
96. Qin W Godec A Zhang X TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death Cancer Med 2019 8 11 5232 5241 10.1002/cam4.2386 31278855
Qin W, Godec A, Zhang X, et al. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death. Cancer Med. 2019;8(11):5232–41.31278855 10.1002/cam4.2386
97. Wang J, Calizo A, Zhang L, et al. CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors. bioRxiv. 2023.
98. Wang J Pollard K Allen AN Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors Cancer Res 2020 80 23 5367 5379 10.1158/0008-5472.CAN-20-1365 33032988
Wang J, Pollard K, Allen AN, et al. Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors. Cancer Res. 2020;80(23):5367–79.33032988 10.1158/0008-5472.CAN-20-1365
99. Yoo KH Kim HS Lee SJ Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series BMC Cancer 2015 15 154 10.1186/s12885-015-1160-x 25885855
Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154.25885855 10.1186/s12885-015-1160-x
100. Nakamura T Matsumine A Kawai A The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study Cancer 2016 122 9 1408 1416 10.1002/cncr.29961 26970174
Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–16.26970174 10.1002/cncr.29961
101. Seto T, Song MN, Trieu M, et al. Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California. Med Sci (Basel). 2019;7(3):48.
